Statement from LuMind Research Down Syndrome Foundation on the Roche Clinical Trials

Categories: Blog, Clinical Trials, Ds Research, News
From LuMind RDS Board Chairman, Ryan Hartman We thank you for turning to LuMind Research Down Syndrome with your questions and comments about the news of the Roche CLEMATIS Phase 2 clinical trial for RG1662/Basmisanil. As the largest source of private funding for Down syndrome cognition research, we are in contact with many people from our …

Read More

Response to the Roche Clinical Trial for CLEMATIS

Categories: Blog, Ds Research, News
A response from LuMind Research Down Syndrome President and CEO Carolyn Cronin regarding the end of the Roche Clinical Trial for CLEMATIS. Hello friends, Like you we were disappointed to learn about the end of Roche Clinical Trial for CLEMATIS, the Phase II study investigating the efficacy and safety of basmisanil (RG1662) in adults and …

Read More

Ann & Dee’s Memorial 24 Hour Relay Run for Research

Categories: Blog, Events, Meet Our Friends, News, Runners Program
Looking for a FUN way to raise money for LuMind Research Down Syndrome Foundation without all the stress of planning a complicated event or gala? Take a look at the Ann & Dee’s Memorial 24 Hour Relay Run for Research! Lisa Arnoa and Matt MacDougall came up with the idea for the the 24 Hour Relay Run for Research …

Read More

Leadership Inspiration: Creativity Through Constraints

Categories: Blog, News
By Alan Gard “Come,” I said to Akila, my new team member. “Let me introduce you to the one who has taught me the most about leadership.” Akila followed. “What are the most important lessons you’ve learned?” she asked. “There are many!” I responded. “The most important are…  ONE: Build a great team. Acting independently …

Read More

Clinical Trial Update: Green Tea’s Effect on Boosting Cognition

Categories: Blog, Clinical Trials, Ds Research, News
News from the phase 2 clinical trial of with a chemical in green tea has been shown to improve cognitive ability in people with Down syndrome, according to researchers from the Centre for Genomic Regulation in Barcelona. The study will be published in The Lancet Neurology, but there are news reports outlining the preliminary results of this interesting …

Read More